This NDC is on FDA's drug shortage list (posted Mar 23, 2018)
Reported reason: Demand increase for the drug
Product Information
KETOROLAC 30 MG/ML VIAL is a generic product labeled by Sagent Pharmaceuticals, priced at $1.0175 per ML under NDC 25021070101. Its NADAC has been published 573 times since Dec 31, 2014.
FDA first approved this application on Nov 1, 2016. Its Orange Book therapeutic-equivalence code is AP.
Strength
30 mg/mL
Manufacturer
Sagent PharmaceuticalsNDC
25021070101
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
KETOROLAC TROMETHAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA204216FDA Approved
11/1/2016
TE Code
AP
On Market Since
9/5/2014
Pharmacological Classes
Price Statistics
The NADAC for KETOROLAC 30 MG/ML VIAL has been published 573 times since Dec 31, 2014, and over the history we have for it it has risen 45.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0175 per ML |
|---|---|
| All-time high | $4.4589 (Nov 16, 2016) |
| All-time low | $0.6973 (Dec 31, 2014) |
| 52-week high | $1.0778 |
| 52-week low | $0.7047 |
| Median price | $1.4492 |
| Average price | $1.7291 |
| Largest weekly change | +94.7% (Aug 17, 2016) |
| Weeks tracked | 573 |
| Tracking since | Dec 31, 2014 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sagent Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ketorolac tromethamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cyclooxygenase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KETOROLAC 30 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for KETOROLAC 30 MG/ML VIAL, manufactured by Sagent Pharmaceuticals, is $1.0175 per ML (NDC 25021070101), effective Sep 30, 2026.
How has the price of KETOROLAC 30 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for KETOROLAC 30 MG/ML VIAL has risen 45.9%. It has been tracked across 573 weekly CMS publications since Dec 31, 2014.
What are the highest and lowest recorded NADAC prices for KETOROLAC 30 MG/ML VIAL?
Since Dec 31, 2014, the NADAC for KETOROLAC 30 MG/ML VIAL has ranged from a low of $0.6973 (Dec 31, 2014) to a high of $4.4589 (Nov 16, 2016), with a median of $1.4492 per ML.
Are there cheaper alternatives to KETOROLAC 30 MG/ML VIAL?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KETOROLAC 60 MG/2 ML VIAL, is $0.5524 per ML — about 46% below KETOROLAC 30 MG/ML VIAL.
Who manufactures KETOROLAC 30 MG/ML VIAL?
KETOROLAC 30 MG/ML VIAL (NDC 25021070101) is labeled by Sagent Pharmaceuticals, and CMS classifies it as a generic product.
Is KETOROLAC 30 MG/ML VIAL in shortage?
Yes — NDC 25021070101 is currently listed in FDA's drug shortage database (posted Mar 23, 2018). Reported reason: Demand increase for the drug.